Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics Inc (APGE) is a clinical-stage biotechnology company pioneering long-acting biologics for inflammatory and immunological conditions including atopic dermatitis, COPD, and asthma. This dedicated news hub provides investors and industry professionals with timely, verified updates on the company’scientific advancements and operational developments.
Access comprehensive coverage of clinical trial milestones, regulatory submissions, and strategic partnerships alongside earnings reports and management commentary. Our curated news collection enables efficient tracking of APGE’s antibody engineering progress, including programs targeting IL-13 and IL-4Rα pathways with enhanced pharmacokinetic profiles.
Key updates include developments in lead candidates APG777 and APG808, manufacturing scale-up announcements, and peer-reviewed research publications. All content undergoes rigorous verification to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Apogee Therapeutics’ latest developments in biologics innovation. Check regularly for objective updates on therapeutic candidates designed to improve dosing frequency and treatment outcomes in chronic inflammatory diseases.
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech company focused on developing biologics for atopic dermatitis, COPD, asthma, and other inflammatory and immunology conditions, announced its participation in two upcoming investor conferences. The Jefferies Global Healthcare Conference will take place on June 6, 2024, at 8:30 a.m. ET, followed by the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 11:20 a.m. ET. Live and archived webcasts of these events will be accessible through the company's website.
Apogee Therapeutics announced the dosing of the first patient in its Phase 2 trial of APG777 for atopic dermatitis (AD). APG777 is a novel subcutaneous monoclonal antibody targeting IL-13, with a half-life extended to approximately 75 days. Phase 1 results indicated a potentially best-in-class profile. The Phase 2 study combines typical Phase 2a and 2b into a single protocol, with an expected 16-week proof-of-concept data in 2H 2025. The trial aims to improve clinical responses with fewer injections. APG777's potential for treating asthma and other inflammatory diseases is also being explored.
Apogee Therapeutics, a clinical-stage biotechnology company, reported pipeline progress and first quarter financial results. The company initiated Phase 2 trials for APG777 targeting atopic dermatitis, dosed the first participant in the Phase 1 trial for APG808 targeting chronic obstructive pulmonary disease, and selected a development candidate for APG990. Additionally, Apogee raised $483 million through a public offering, maintaining a cash position of $816 million. Despite positive pipeline advancements, the company reported an increase in R&D and G&A expenses resulting in a net loss of $32.1 million for the first quarter of 2024.
Apogee Therapeutics, a clinical-stage biotechnology company, will participate in the 2024 Bank of America Healthcare Conference. The CEO and CFO will engage in a fireside chat to discuss the company's advancements in biologics for various medical conditions. The event will be webcasted for investors.
FAQ
What is the current stock price of Apogee Therapeutics (APGE)?
What is the market cap of Apogee Therapeutics (APGE)?
